Natera and CytoDyn Announce Strategic Collaboration
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2026
0mins
Natera (NTRA) and CytoDyn Inc. (CYDY) announced a strategic collaboration to evaluate circulating tumor DNA dynamics and generate real-world molecular insights to support CytoDyn's metastatic colorectal cancer development program. Under the agreement, Natera will assess CytoDyn clinical trial samples from the CLOVER Phase 2 study in patients with mCRC. Signatera, Natera's personalized assay for the detection of molecular residual disease, will be used to evaluate ctDNA dynamics and molecular response patterns associated with leronlimab treatment. Natera will also provide customized real-world data analyses leveraging its proprietary oncology database, which is the largest multi-timepoint early- and late-stage oncology dataset with more than 2 million plasma timepoints and enriched clinical and imaging records. By integrating molecular response data from its MRD testing platform with curated electronic medical record data, this multimodal dataset enables analyses of patient populations, treatment patterns, ctDNA response rates, and response dynamics across diverse clinical settings. Together, these capabilities are expected to generate insights into molecular response and disease progression that may help inform future clinical development of leronlimab, including clinical trial design, biomarker-driven patient selection strategies, and broader translational research efforts. The collaboration builds on CytoDyn's growing oncology program and follows completion of enrollment in the CLOVER study, which is evaluating leronlimab in combination with trifluridine/tipiraci and bevacizumab in patients with previously treated mCRC. The collaboration is also expected to complement ongoing translational and biomarker analyses from the study aimed at further characterizing treatment response and informing future development strategies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTRA
Wall Street analysts forecast NTRA stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 226.440
Low
205.00
Averages
262.92
High
300.00
Current: 226.440
Low
205.00
Averages
262.92
High
300.00
About NTRA
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Natera Showcases New Prospera Test Data at American Transplant Congress
- Clinical Utility Enhancement: Natera will present 21 presentations, including seven oral ones, at the 2026 American Transplant Congress, emphasizing the Prospera test's effectiveness in risk assessment and long-term monitoring across kidney, heart, and multi-organ transplants, which is expected to enhance clinical decision-making.
- Key Data Revealed: Among 346 kidney transplant patients, 18.2% with positive Prospera results were associated with significantly higher graft loss rates, indicating over six times the risk of graft loss, suggesting that elevated Prospera dd-cfDNA levels can predict adverse outcomes even when biopsy results are negative.
- Monitoring Capability Improvement: In a study of 989 kidney transplant recipients, patients with Prospera dd-cfDNA levels below 0.5% had significantly lower adverse outcome rates, with approximately 12 times reduced odds of future rejection, underscoring the importance of regular monitoring.
- Strategic Implications: Natera's Chief Medical Officer stated that the regular use of the Prospera test as a non-invasive monitoring tool could support longer graft survival and better clinical outcomes, further solidifying the company's leadership position in the precision medicine field.
See More
NTRA Stock Shows Potential for Breakout
- Trendline Test: NTRA stock has been in an uptrend for most of the past three years, and its recent successful test of the uptrend line suggests the potential for another multi-month advance.
- Price Target: Should NTRA break out from its current trading pattern, the measured move target would be near 263, with a stop loss set at 203, indicating strong upside potential.
- Relative Strength Performance: Since late 2022, NTRA has outperformed the XLV Healthcare ETF, consistently breaking out of consolidation patterns, which highlights its competitive position within the industry.
- Historical Pattern Review: Each of the four prior tests of the uptrend line resulted in significant upside, indicating that a breakout from the key resistance area could trigger a similar upward trend.
See More
U.S. Government May Challenge IARC Cancer Assessments
- Government Position Statement: The U.S. Department of Health and Human Services (HHS) and the State Department jointly released a statement indicating a potential challenge to cancer hazard assessments issued by the International Agency for Research on Cancer (IARC), arguing that IARC's findings often blur the line between hazard and true risk, undermining independently verified results from other research institutions.
- Scientific Research Critique: The statement criticized IARC's classification of processed meats as a Group 1 carcinogen, equating it with tobacco smoking, asserting that such oversimplification fails to effectively inform public health policy and could negatively impact the health of the American populace.
- Call for Policy Transparency: HHS and the State Department emphasized that public health decisions should be made by American institutions accountable to the public, ensuring that decision-making processes are transparent and evidence-based, reflecting U.S. interests and scientific standards rather than relying on organizations whose findings may not fully align with U.S. law and policy.
- New Direction in Health Policy: HHS Secretary Robert F. Kennedy Jr.'s controversial unveiling of a new inverted food pyramid in January, which prioritizes protein, dairy, healthy fats, and fruits and vegetables, indicates a shift in U.S. public health policy towards a more domestically focused approach.
See More
JGRO Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: JGRO's 52-week low is $81.16 and high is $99.73, with the last trade at $97.19, indicating price volatility near the high point, which may influence investor buying decisions.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs highlights those experiencing significant inflows or outflows, which can affect the underlying stocks held within the ETFs and subsequently impact overall market performance.
See More
Stanley Druckenmiller Invests in Natera
- Portfolio Highlight: Stanley Druckenmiller's current $600 million investment in Natera represents 18% of his portfolio, indicating strong confidence in the healthcare company despite its market cap of only $30 billion.
- Revenue Growth Potential: Natera reported $2.3 billion in revenue last year, a 35% year-over-year increase, with expectations to reach $2.8 billion this year and $3.3 billion next year, showcasing robust growth momentum in the genetic testing market.
- Broad Market Outlook: According to industry research, the global genetic testing market is projected to grow at an average annual rate of over 11% through 2035, potentially exceeding $70 billion, positioning Natera to capture a significant share of this growth.
- Profitability Outlook: Although Natera is not yet profitable, analysts expect its per-share loss to decrease from $1.58 this year to $0.32 next year, with a projected profit of $1.43 per share by fiscal 2028, indicating a promising path toward profitability.
See More
Natera Partners with Diakonos to Evaluate New Therapy
- Collaboration Background: Natera has partnered with Diakonos Oncology Corp. to utilize Signatera™ for assessing molecular responses in patients with refractory melanoma enrolled in the DOC-RM clinical trial, marking a significant advancement in precision medicine for cancer treatment.
- Clinical Trial Progress: The DOC-RM trial, which began enrollment in May, evaluates the FDA Fast Track-designated DOC1021 therapy, aiming to provide new treatment options for patients with unresectable or metastatic cutaneous melanoma, indicating potential positive impacts on patient outcomes.
- Technical Advantage: By analyzing circulating tumor DNA (ctDNA) at multiple timepoints, Natera's Signatera test can offer earlier insights into molecular responses compared to traditional imaging, enabling physicians to better understand treatment dynamics and optimize therapeutic strategies.
- Market Demand: Patients with refractory melanoma face significant unmet medical needs, and the collaboration between Natera and Diakonos not only aims to address this gap but also has the potential to drive the development of new therapies, enhancing patient survival rates and quality of life.
See More
Natera Showcases New Prospera Test Data at American Transplant Congress
- Clinical Utility Enhancement: Natera will present 21 presentations, including seven oral ones, at the 2026 American Transplant Congress, emphasizing the Prospera test's effectiveness in risk assessment and long-term monitoring across kidney, heart, and multi-organ transplants, which is expected to enhance clinical decision-making.
- Key Data Revealed: Among 346 kidney transplant patients, 18.2% with positive Prospera results were associated with significantly higher graft loss rates, indicating over six times the risk of graft loss, suggesting that elevated Prospera dd-cfDNA levels can predict adverse outcomes even when biopsy results are negative.
- Monitoring Capability Improvement: In a study of 989 kidney transplant recipients, patients with Prospera dd-cfDNA levels below 0.5% had significantly lower adverse outcome rates, with approximately 12 times reduced odds of future rejection, underscoring the importance of regular monitoring.
- Strategic Implications: Natera's Chief Medical Officer stated that the regular use of the Prospera test as a non-invasive monitoring tool could support longer graft survival and better clinical outcomes, further solidifying the company's leadership position in the precision medicine field.
See More
NTRA Stock Shows Potential for Breakout
- Trendline Test: NTRA stock has been in an uptrend for most of the past three years, and its recent successful test of the uptrend line suggests the potential for another multi-month advance.
- Price Target: Should NTRA break out from its current trading pattern, the measured move target would be near 263, with a stop loss set at 203, indicating strong upside potential.
- Relative Strength Performance: Since late 2022, NTRA has outperformed the XLV Healthcare ETF, consistently breaking out of consolidation patterns, which highlights its competitive position within the industry.
- Historical Pattern Review: Each of the four prior tests of the uptrend line resulted in significant upside, indicating that a breakout from the key resistance area could trigger a similar upward trend.
See More
U.S. Government May Challenge IARC Cancer Assessments
- Government Position Statement: The U.S. Department of Health and Human Services (HHS) and the State Department jointly released a statement indicating a potential challenge to cancer hazard assessments issued by the International Agency for Research on Cancer (IARC), arguing that IARC's findings often blur the line between hazard and true risk, undermining independently verified results from other research institutions.
- Scientific Research Critique: The statement criticized IARC's classification of processed meats as a Group 1 carcinogen, equating it with tobacco smoking, asserting that such oversimplification fails to effectively inform public health policy and could negatively impact the health of the American populace.
- Call for Policy Transparency: HHS and the State Department emphasized that public health decisions should be made by American institutions accountable to the public, ensuring that decision-making processes are transparent and evidence-based, reflecting U.S. interests and scientific standards rather than relying on organizations whose findings may not fully align with U.S. law and policy.
- New Direction in Health Policy: HHS Secretary Robert F. Kennedy Jr.'s controversial unveiling of a new inverted food pyramid in January, which prioritizes protein, dairy, healthy fats, and fruits and vegetables, indicates a shift in U.S. public health policy towards a more domestically focused approach.
See More
JGRO Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: JGRO's 52-week low is $81.16 and high is $99.73, with the last trade at $97.19, indicating price volatility near the high point, which may influence investor buying decisions.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs highlights those experiencing significant inflows or outflows, which can affect the underlying stocks held within the ETFs and subsequently impact overall market performance.
See More
Stanley Druckenmiller Invests in Natera
- Portfolio Highlight: Stanley Druckenmiller's current $600 million investment in Natera represents 18% of his portfolio, indicating strong confidence in the healthcare company despite its market cap of only $30 billion.
- Revenue Growth Potential: Natera reported $2.3 billion in revenue last year, a 35% year-over-year increase, with expectations to reach $2.8 billion this year and $3.3 billion next year, showcasing robust growth momentum in the genetic testing market.
- Broad Market Outlook: According to industry research, the global genetic testing market is projected to grow at an average annual rate of over 11% through 2035, potentially exceeding $70 billion, positioning Natera to capture a significant share of this growth.
- Profitability Outlook: Although Natera is not yet profitable, analysts expect its per-share loss to decrease from $1.58 this year to $0.32 next year, with a projected profit of $1.43 per share by fiscal 2028, indicating a promising path toward profitability.
See More
Natera Partners with Diakonos to Evaluate New Therapy
- Collaboration Background: Natera has partnered with Diakonos Oncology Corp. to utilize Signatera™ for assessing molecular responses in patients with refractory melanoma enrolled in the DOC-RM clinical trial, marking a significant advancement in precision medicine for cancer treatment.
- Clinical Trial Progress: The DOC-RM trial, which began enrollment in May, evaluates the FDA Fast Track-designated DOC1021 therapy, aiming to provide new treatment options for patients with unresectable or metastatic cutaneous melanoma, indicating potential positive impacts on patient outcomes.
- Technical Advantage: By analyzing circulating tumor DNA (ctDNA) at multiple timepoints, Natera's Signatera test can offer earlier insights into molecular responses compared to traditional imaging, enabling physicians to better understand treatment dynamics and optimize therapeutic strategies.
- Market Demand: Patients with refractory melanoma face significant unmet medical needs, and the collaboration between Natera and Diakonos not only aims to address this gap but also has the potential to drive the development of new therapies, enhancing patient survival rates and quality of life.
See More
